A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms Keyriched-1
Most Recent Events
- 04 Jun 2024 Results of biomarker analysis for pCR in the single arm, in HER2-E eBC treated with pembrolizumab and dual HER2 blockade, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 10 Dec 2022 Results of translational subproject (n=42) assessing the gene signatures together with tumor cell proliferation and spatiotemporal immune cell profiling to identify predictive factors for pCR of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer, presented at the 45th Annual San Antonio Breast Cancer Symposium.
- 29 Jun 2022 Status changed from recruiting to completed.